Welcome to our dedicated page for Vincerx Pharma news (Ticker: VINC), a resource for investors and traders seeking the latest updates and insights on Vincerx Pharma stock.
Vincerx Pharma, Inc. (VINC) generates news that reflects both its history as a clinical-stage oncology biopharmaceutical company and its more recent transition toward dissolution and liquidation. Earlier announcements describe Vincerx’s efforts to develop differentiated cancer therapies, including antibody-drug conjugates, a small molecule drug conjugate, a CDK9 inhibitor, a preclinical ADC, and the VersAptx bioconjugation platform. These disclosures provide context for news related to its pipeline and strategic collaborations.
More recent news coverage focuses on Vincerx’s corporate and capital markets developments. The company has issued multiple press releases about a Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of the company under a Plan of Liquidation and Dissolution. These releases detail adjournments of the meeting, the board’s unanimous recommendation that stockholders vote for the Dissolution Proposal, and estimated ranges of potential per-share distributions that could be available following approval, subject to assumptions and ongoing costs.
Other notable news items include Vincerx’s announcement of its intention to file a Form 25 to delist and deregister its common stock from The Nasdaq Stock Market, citing a Nasdaq delisting notice related to minimum bid price requirements and the board’s decision to dissolve and wind up the business. The company has also reported a 1-for-20 reverse stock split, terminations of binding term sheets and letters of intent for proposed mergers and reverse mergers, and the board’s evaluation of strategic alternatives such as out-licensing, asset sales, and potential wind-down.
Investors and observers following VINC news can expect updates on the status of the Dissolution Proposal, any changes to estimated distribution ranges, developments in the wind-down of operations, and regulatory or listing matters. Historical news also offers insight into Vincerx’s prior strategic merger discussions with Oqory, Inc. and its non-binding letter of intent with QumulusAI. This page serves as an archive of these corporate, strategic, and regulatory developments for Vincerx Pharma, Inc.
Vincerx Pharma, Inc. (Nasdaq: VINC) announced three poster presentations for the 64th American Society of Hematology (ASH) Annual Meeting, set for December 10-13, 2022, in New Orleans and virtually. Key presentations include:
- VIP943: A novel CD123 antibody drug conjugate for acute myeloid leukemia (AML).
- Enitociclib: A CDK9 inhibitor showing safety and early efficacy signs in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
- Preclinical Study: Enitociclib's combination studies in multiple myeloma.
Details and materials will be available on the company's website after the presentations.
Vincerx Pharma reported its Q2 2022 financial results, highlighting key advancements in its clinical pipeline. The company has $80.9 million in cash, sufficient to fund operations through late 2024. The second-quarter net loss widened to $18.4 million, or $0.88 per share, up from a net loss of $2.0 million in Q2 2021. Key developments include the recent issuance of the INN for VIP152, enitociclib, and ongoing IND submissions for VIP236, VIP943, and VIP924. The firm is focused on prioritized studies in high-grade B-cell lymphoma and chronic lymphocytic leukemia.
Vincerx Pharma presented compelling new clinical data on VIP152, a selective CDK9 inhibitor, at the EHA 2022 Congress. The data revealed VIP152 demonstrated early signs of clinical efficacy and a favorable cardiac safety profile in lymphoma patients. Notably, VIP152 achieved robust MYC mRNA downregulation, along with showing effectiveness in CLL patients resistant to prior therapies. A pooled analysis indicated manageable neutropenia, supporting its potential as a treatment for high-grade B-cell lymphomas. Vincerx aims to prioritize its clinical program for double-hit DLBCL and CLL based on these positive outcomes.
Vincerx Pharma (Nasdaq: VINC) has announced a strategic update to focus resources on key clinical trials for VIP152, targeting double-hit DLBCL and high-risk CLL. The company plans to streamline operations by reducing full-time employees by 33% and extending its cash runway into late 2024. Vincerx aims to file IND applications for VIP236 and VIP943 in the second half of 2022 and 2023, respectively. Recent clinical trials for VIP152 have shown stable disease in certain patients, guiding the company toward a prioritized approach in its oncology programs.
Vincerx Pharma reported its Q1 2022 financial results, revealing a net loss of $16.4 million, or $0.79 per share, compared to a loss of $6.3 million, or $0.46 per share, in Q1 2021. The company had $96.5 million in cash as of March 31, 2022, down from $111.5 million at year-end 2021, but expects sufficient resources to cover operations through 2023. Vincerx continues clinical studies for VIP152, targeting various malignancies, and plans to file INDs for VIP236, VIP943, and VIP924 in the second half of 2022 and 2023.
Vincerx Pharma (VINC) presented promising preliminary results for VIP152, a PTEFb/CDK9 inhibitor targeting gynecologic cancers, at the AACR Annual Meeting 2022. Preclinical data showed VIP152 effectively inhibits tumor growth in ovarian cancer models. Initial clinical results indicated stable disease in all MYC-amplified patients. The trial demonstrated VIP152's potential for treating various MYC and MCL-1-driven tumors, with manageable toxicity. Ongoing Phase 1b studies continue to enroll patients across multiple tumor types.
Vincerx Pharma has dosed its first patient in the VIP152 and pembrolizumab combination trial, part of the Phase 1b study. The Company also plans to initiate Phase 2 studies of VIP152 in the second half of 2022. It obtained IND approval for the small molecule drug conjugate VIP236, aiming for IND filing in 2H2022. Vincerx reported a net loss of $39.3 million for 2021, with R&D expenses reaching $40.1 million. The company holds $111.5 million in cash, sufficient for operations through 2023, and is funded by a German government research allowance of up to EUR 6 million.
Vincerx Pharma, a clinical-stage biopharmaceutical company, announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, scheduled for April 8-13, 2022, in New Orleans and virtually. The poster, titled "VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy," will be presented by Melanie Frigault, PhD, on April 11 at 1:30 PM CT. Presentation materials will be available on Vincerx's website after the event.
PALO ALTO, Calif., Feb. 09, 2022 – Vincerx Pharma, a biopharmaceutical company focused on innovative cancer therapeutics, announced participation in the upcoming SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The management team will engage in a fireside chat on February 17, 2022, at 1:40 PM ET. Investors can access the live webcast and archived recordings via Vincerx's website. The company aims to address unmet medical needs with its advanced oncology therapies, including a pipeline developed from an exclusive partnership with Bayer.
Vincerx Pharma (Nasdaq: VINC) announced positive preclinical data for VIP236, a novel small molecule-drug conjugate targeting aggressive tumors. Published in the journal Cancers, the research highlights VIP236's ability to deliver a potent chemotherapy payload directly to cancer cells while sparing healthy tissue. The study showcases a 40-fold increase in drug delivery to tumors compared to normal tissues and demonstrates superior tumor targeting and tolerability in various cancer models. Vincerx plans to advance VIP236 into clinical trials in late 2022.
FAQ
What is the current stock price of Vincerx Pharma (VINC)?
What is the market cap of Vincerx Pharma (VINC)?
